Breast Neoplasms Clinical Trial
Official title:
A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer
Verified date | March 2024 |
Source | Baylor Breast Care Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy of sitravatinib in patients with metastatic breast cancer. All study participants will receive sitravatinib, 120 mg daily, until their cancer worsens, or until they develop intolerable side effects.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 22, 2021 |
Est. primary completion date | September 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Women or men age 18 and older - Metastatic or locally advanced inoperable disease breast cancer - Tumor is estrogen receptor (ER) negative and progesterone receptor (PR) negative per the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines of 2010. - Tumor is HER2neu negative per ASCO/CAP Guidelines of 2018 - Patient has tumor tissue blocks from metastatic or locally advanced breast cancer (beyond curative management) for the analysis of PTPN12 status - Metastatic disease or locally advanced breast cancer (beyond curative management) that is measurable according to RECIST 1.1 criteria. Patients with bone only disease are eligible for enrollment if there is at least one lytic lesion that can be followed for response. - At least one prior line of chemotherapy with or without a PDL1 or PD1 antibody in metastatic setting - Patient has Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky > 60%) - Patients must have normal organ and marrow function as defined below: - Absolute neutrophil count > 1000/mcL - Hemoglobin > 11 g/dL - Platelets >100,000/mcL - Total bilirubin < 1.5 X normal institutional limits - Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal (ULN) or = 5.0 × ULN for patients with documented liver metastases. - Creatinine within normal institutional limits - Creatinine clearance > 30 mL/min/1.73 m2 - Normal left ventricular ejection (LVEF) function defined as normal left ventricular wall motion and ejection fraction of = 50%. - If patient has brain metastasis, documented treatment and stability for at least 30 days by scans and off steroids at the time of enrollment - Women of child bearing age and actively menstruating must have a negative pregnancy test prior to study enrollment. - Ability to understand and the willingness to give informed consent Exclusion Criteria: - Untreated hypertension defined as systolic blood pressure > 140 and/or diastolic blood pressure > 90 on two or more occasions within the past 30 days previous to enrollment - Imaging suggestive of Lymphangitic carcinomatosis in the lung, or use of home oxygen - Untreated brain metastases. - Pregnancy or lactation at time of trial enrollment - Concomitant metastatic disease of another tumor type - Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs - History of stroke, pulmonary embolus (PE), or myocardial infarction (MI) at any time - Known Proteinuria of = 2 g/24 h - HIV-positive participants. - History of Hepatitis C and Hepatitis B infection - Documented history of congestive heart failure, and/or LVEF less than 50% - Concurrent use of medications on the prohibited medications list, unless these medications can be replaced by alternatives. These medications need to be discontinued at least 2 weeks prior to enrollment. - Presence of other medical condition that, in the sole judgment of the principal investigator, makes the patient not a good candidate. |
Country | Name | City | State |
---|---|---|---|
United States | Baylor College of Medicine | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
C. Kent Osborne, MD | Mirati Therapeutics Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Benefit Rate | Clinical Benefit Rate is defined as Objective Response Rate (ORR) plus Stable Disease (SD) for 24 weeks as per Response Evaluation Criteria In Solid Tumours (RECIST) v1.1. ORR is defined Complete Response plus Partial Response per RECIST v1.1 criteria. | 24 weeks | |
Secondary | Time to Progression | Time to progression is calculated from Day 1 of sitravatinib therapy to first evidence of disease progression, as determine by Response Evaluation Criteria in Solid Tumors (RECIST). | Up to 5 years | |
Secondary | Number of patients with Grade 3 or higher adverse events | Adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria version 5.0. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03698942 -
Delphinus SoftVue™ ROC Reader Study
|
||
Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Not yet recruiting |
NCT02141139 -
Perioperative Inflammation and Breast Cancer Outcome
|
Phase 3 |